<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-141012</identifier>
<setSpec>0025-7753</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Sodium-glucose co-transporter-2 inhibitors: from the bark of apple trees and familial renal glycosuria to the treatment of type 2 diabetes mellitus</dc:title>
<dc:description xml:lang="en">The therapeutic armamentarium for the treatment of hyperglycemia in type 2 diabetes mellitus is still inadequate. We are currently witnessing the introduction of a new mode of hypoglycemic treatment through induction of glycosuria to decrease the availability of the metabolic substrate, i.e. glucose. Clinical trials have shown that sodium-glucose co-transporter-2 (SGLT2) inhibitors are as efficacious as other oral hypoglycemic drugs. This article discusses the basic features of this new treatment concept and the efficacy and safety of this new drug group (AU)</dc:description>
<dc:creator>Mauricio, Dídac</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">El arsenal terapéutico para el tratamiento de la hiperglucemia en la diabetes mellitus tipo 2 aún es insuficiente. Actualmente asistimos a la introducción de una nueva vía en el tratamiento hipoglucemiante a través de la inducción de glucosuria para disminuir la disponibilidad del sustrato metabólico, esto es, la glucosa. Los inhibidores del cotransportador de sodio/glucosa tipo 2 han mostrado en los ensayos clínicos una eficacia comparable a otros fármacos hipoglucemiantes orales. En este artículo se discuten los aspectos básicos generales de este nuevo concepto de tratamiento, y de la eficacia y seguridad de este nuevo grupo terapéutico (AU)</dc:description>
<dc:source>Med. clín (Ed. impr.);141(supl.2): 31-35, nov. 2013. ilus, tab</dc:source>
<dc:identifier>ibc-141012</dc:identifier>
<dc:title xml:lang="es">Inhibidores SGLT-2: de la corteza del manzano y la glucosuria familiar al tratamiento de la diabetes mellitus tipo 2</dc:title>
<dc:subject>^d3946^s22057</dc:subject>
<dc:subject>^d6172^s22044</dc:subject>
<dc:subject>^d7182^s22078</dc:subject>
<dc:subject>^d11121^s22073</dc:subject>
<dc:subject>^d6105^s22078</dc:subject>
<dc:subject>^d6105^s22073</dc:subject>
<dc:subject>^d1718^s22021</dc:subject>
<dc:subject>^d24613^s22073</dc:subject>
<dc:subject>^d35932^s29165</dc:subject>
<dc:subject>^d12345</dc:subject>
<dc:subject>^d6091^s22044</dc:subject>
<dc:subject>^d50911^s22006</dc:subject>
<dc:subject>^d6171^s22036</dc:subject>
<dc:subject>^d330^s22021</dc:subject>
<dc:subject>^d24613^s22078</dc:subject>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d3946^s22044</dc:subject>
<dc:subject>^d6172^s22033</dc:subject>
<dc:subject>^d6169^s22078</dc:subject>
<dc:subject>^d14260^s22073</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d14260^s22078</dc:subject>
<dc:subject>^d6169^s22073</dc:subject>
<dc:subject>^d50911^s22033</dc:subject>
<dc:subject>^d50911^s22031</dc:subject>
<dc:subject>^d7865^s22021</dc:subject>
<dc:subject>^d35995^s29165</dc:subject>
<dc:subject>^d841</dc:subject>
<dc:subject>^d7865^s22044</dc:subject>
<dc:subject>^d1581^s22078</dc:subject>
<dc:subject>^d1581^s22073</dc:subject>
<dc:subject>^d11121^s22001</dc:subject>
<dc:subject>^d7182^s22073</dc:subject>
<dc:subject>^d30782</dc:subject>
<dc:type>article</dc:type>
<dc:date>201311</dc:date>
</metadata>
</record>
</ibecs-document>
